Ceramidase Deficiency Clinical Trial
Official title:
Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease
| Verified date | January 2020 |
| Source | Enzyvant Farber GmbH |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The primary objective of this study is to establish the natural history of Farber disease
(acid ceramidase deficiency) through the collection and analysis of retrospective and
prospective data on patients diagnosed with Farber disease. All patients diagnosed with
Farber disease are eligible, including both those who have and have not undergone
hematopoietic stem cell transplantation (HSCT). Additionally, data and records from deceased
patients will provide valuable retrospective data for this study.
The secondary objective of the study is to establish a set of clinical data, laboratory data
(biomarkers), and functional data potentially useful for:
- Assessing the efficacy of HSCT and the efficacy of potential future therapies (for
example with RVT-801, recombinant human acid ceramidase) in Farber disease
- Characterizing changes in symptoms of patients over time
- Characterizing distinct groups (phenotypes) within the patient population
- Documenting the disease histories of individual patients to serve as intra-subject
control data for those who may enroll in any future clinical studies with therapies for
Farber disease
The exploratory objectives of the study are:
- To explore the relationship between patient disease activity or phenotype and specific
ceramide levels or specific immunologic markers (cytokines/chemokines) in blood
- To evaluate a standardized tool, the Farber Disease Natural History Instrument (FDNI),
to be used for the collection of patient history information, data from clinical,
laboratory, genetic, and functional studies, and data from review of medical records
| Status | Completed |
| Enrollment | 45 |
| Est. completion date | December 9, 2019 |
| Est. primary completion date | October 12, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Living or deceased subjects with diagnosis of Farber disease, based on clinical (typical clinical symptoms) and biochemical and/or genetic criteria, as follows: - Biochemical: An acid ceramidase activity value in white blood cells, cultured skin fibroblasts or other biological sources (e.g., plasma) that is less than 30% of control (normal) values established by the testing laboratory. For deceased subjects only, storage of ceramide in cells from histopathologic sections is also adequate to confirm the diagnosis. - Genetic: Nucleotide changes within both alleles of the acid ceramidase gene (ASAH1) or cDNA that indicate, through bioinformatics, gene expression studies, or other methods, a possible loss of function of the acid ceramidase protein. - Informed consent or assent, for living subjects. For deceased subjects it is the responsibility of the principal investigator to ensure that the proper requirements are met according to local laws and regulations. Exclusion Criteria: • Current use or history of use in the past 30 days of an investigational agent (with exception of off-label use of medications). |
| Country | Name | City | State |
|---|---|---|---|
| Argentina | Hospital de Niños de la Santisima Trinidad | Córdoba | CP |
| Canada | Montreal Children's Hospital | Montreal | Quebec |
| Egypt | Cairo University | Cairo | |
| Germany | Universitätsklinikum Giessen, Zentrum für Kinderheilkunde und Jugendmedizin | Giessen | Hessen |
| India | Lok Nayak Hospital & Maulana Azad Medical College | Dehli | |
| India | Sir Ganga Ram Hospital | Delhi | |
| Italy | IRCCS Istituto Giannina Gaslini | Genoa | |
| Italy | University of Milan | Milan | |
| Sweden | Astrid Lindgrens barnsjukhus, Karolinska University Hospital Solna | Stockholm | |
| Turkey | Cukurova University School of Medicine | Adana | |
| Turkey | Hacettepe University Medical Faculty Hospital | Ankara | |
| Turkey | Istanbul University Istanbul School of Medicine | Istanbul | |
| Turkey | Dokuz Eylul University School of Medicine | Izmir | |
| United States | UCSF Benioff Children's Hospital Oakland | Oakland | California |
| United States | Children's National Health System | Washington | District of Columbia |
| Lead Sponsor | Collaborator |
|---|---|
| Enzyvant Farber GmbH |
United States, Argentina, Canada, Egypt, Germany, India, Italy, Sweden, Turkey,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Establish a dataset on the natural history of Farber Disease | Collection of information for all subjects will include data from: Medical history Farber disease diagnosis, presentation, treatments and symptom progression Collection of information from living subjects will include: Medical examination Disease-specific data (Farber Disease Natural History Instrument - FDNI) Laboratory tests (laboratory assessments and inflammatory markers) Functional tests Six-minute walk test (6MWT) Pulmonary function testing Additional assessments and evaluations: Patient reported outcomes Pain assessment Relative impact of symptoms Nodule Impact Questionnaire Physician and Patient/Parent global assessment Measurement and clinical characteristics of index nodules Ultrasound evaluation of liver and spleen High-frequency ultrasound |
Up to 21 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02298634 -
Biomarker for Farber Disease (BioFarber)
|